Evidence map›Paper›PMID 27312260›Full record

Trial reportThe AAPS journal2016

Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process.

Bipin Mistry, Nikunjkumar Patel, Masoud Jamei, Amin Rostami-Hodjegan, Marilyn N Martinez

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The AAPS journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bipin MistryOffice of New Drug Evaluation, Center for Veterinary Medicine, US FDA, Rockville, Maryland, 20855, USA.
Nikunjkumar PatelSimcyp (a Certera company), Blades Enterprise Centre, Sheffield, UK.
Masoud JameiSimcyp (a Certera company), Blades Enterprise Centre, Sheffield, UK.
Amin Rostami-HodjeganSimcyp (a Certera company), Blades Enterprise Centre, Sheffield, UK.
Marilyn N MartinezOffice of New Drug Evaluation, Center for Veterinary Medicine, US FDA, Rockville, Maryland, 20855, USA. marilyn.martinez@fda.hhs.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The attention and interest in establishing in vivo/in vitro correlations (IVIVCs) is grounded in its tremendous utility as a prognostic tool. It can be used to support formulation optimization, predict in vivo drug exposure across a potential patient population, select a biologically relevant in vitro dissolution test condition, and support the use of in vitro dissolution data as a surrogate for in vivo bioequivalence trials. The pharmacological and statistical implications of this correlation are linked to the method by which the IVIVC was determined and to the assumptions and optimization approaches integrated into the estimation procedure. Using previously published data generated in normal healthy volunteers, an IVIVC for metoprolol was established using a mechanistic modeling approach. Within that framework, we explored the consequences of (1) our method of fitting a single Weibull function to the in vivo dissolution, (2) our selection of weighting scheme and optimization approaches, (3) the impact of applying a fixed versus fitted gastric emptying time, and 4) the importance of factoring population variability into our IVIVC estimation and profile reconvolution. We identified those factors found to be critical in terms of their influence on the accuracy of our predicted systemic metoprolol concentration-time profiles. We considered the strengths and weaknesses of our approach and discussed how the results of this study may impact efforts to generate IVIVCs with compounds presenting physicochemical characteristics different from that of metoprolol.

Indexed as

Models, TheoreticalAdministration, OralAdolescentAdultChemistry, PharmaceuticalCross-Over StudiesCytochrome P-450 CYP2D6Delayed-Action PreparationsFemaleHumansMaleMetoprololMiddle AgedYoung AdultCytochrome P-450 CYP2D6Delayed-Action PreparationsMetoprololin vivo/in vitro correlationmechanistic modelmetoprolol

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.